Predict your next investment

Corporation
HEALTHCARE | Biotechnology
osepharma.com

See what CB Insights has to offer

Stage

IPO | IPO

Date of IPO

3/31/2015

About OSE Pharma

OSE Pharma (Paris: OSE) is a biotechnology company that designs and develops cancer immunotherapy treatments aimed at re-educating the immune system to fight cancer while preserving patients' quality of life.

OSE Pharma Headquarter Location

Pepiniere Paris Sante Cochin 29 bis rue du Faubourg Saint Jacques

Paris, 75014,

France

+33 (0) 1 43 29 78 57

Latest OSE Pharma News

Ose Pharma gets clinical milestone for IL7R antagonist

Feb 8, 2019

European Biotechnology Latest News Ose Pharma gets clinical milestone for IL7R antagonist Suggested mode of action of OSE-127: Blocking of an epitope overlapping theIL-7 binding domain and the receptor heterodimerization region prevents activation of JAK/STAT signaling as well as PI3K and Erksignaling, which blocks inflammation by neutralisation of IFN-gamma producing antigen-specific memory T cells © Nature Communicationsvolume 9, Article number: 4483 (2018) 08.02.2019 by tg Ose Immunotherapeutics has got the first milestone payment within its €272m deal with Servier inked in 2016. Under the deal inked in 2016, immuno-oncology and autoimmune specialist Ose Immunotherapeutics develops its IL-7-receptor antagonist OSE-127 until Phase II proof of concept in ulcerative colitis while Servier has the option to licence it for global commercialisation in autoimmune disorders and chronic inflammation. The Nantes-based company, who enroled the first volunteers into a Phase I trail in December 2018, now achieved step one – an undisclosed development milestone – of the  two-step option agreement cashing in a €10m milestone payment. OSE-127 is an anti-CD127 monoclonal antibody targeting the alpha chain of the interleukin-7 receptor (IL-7R) on T effector cells. Binding of OSE-127 to CD127 inhibits receptor dimer internalisation and was recently shown to prevent the migration of pathogenic T lymphocytes while preserving regulatory T lymphocytes, which carry only few IL.7 receptors at its surface. Experiments in non-human primates suggest that blocking of receptor signalling shifts the Teff/Treg balance towards the immune-dampening Tregs, which could have a positive impact in a range of autoimmune diseases including autoimmune colitis, multiple sclerosis, type-1 diabetes, rheumatoid arthritis, systemic lupus erythematosus, and primary Sjӧgren’s syndrome. Servier also wants to develop OSE-127 in Sjögren’s syndrome, the second most frequent auto-immune disease. Share

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing OSE Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

OSE Pharma is included in 1 Expert Collection, including Pharma Startups.

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

OSE Pharma Patents

OSE Pharma has filed 2 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immune system
  • Immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/28/2016

3/13/2018

Clusters of differentiation, Immune system, Transcription factors, Immunology, Proteins

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

6/28/2016

00/00/0000

Grant Date

3/13/2018

00/00/0000

Title

Subscribe to see more

Related Topics

Clusters of differentiation, Immune system, Transcription factors, Immunology, Proteins

Subscribe to see more

Status

Grant

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.